NIH Highlighted Topic: GLP-1s: Implications for Nutritional Status and Metabolic Health Outcomes
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on understanding how GLP-1 receptor agonists (GLP-1s) impact nutritional status, metabolism, chronic disease outcomes, and population health. This highlighted topic supports multidisciplinary projects designed to investigate the biological, behavioral, clinical, and societal implications of rapidly expanding GLP-1 use, including both prescription therapies and dietary supplements marketed as “GLP-1 mimetics.”
NIH is particularly interested in research examining how GLP-1 therapies influence nutrient metabolism, body composition, appetite regulation, gastrointestinal function, microbiome composition, metabolic biomarkers, and long-term health outcomes. Companies developing AI-enabled nutrition analytics platforms, metabolic monitoring systems, digital therapeutics, wearable health technologies, precision nutrition platforms, dietary supplement testing systems, or real-world evidence platforms may be strong candidates for funding.
Areas of interest include metabolic health biomarkers, obesity and diabetes management, cancer prevention and survivorship, cardiovascular risk reduction, aging and cognitive outcomes, musculoskeletal health, ocular disease mechanisms, oral health effects, microbiome changes, and lifestyle interventions supporting GLP-1 treatment. NIH is also encouraging projects focused on the safety, composition, efficacy, and biological mechanisms of supplements marketed as GLP-1 mimetics, including interactions with prescription GLP-1 medications.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for additional commercialization and follow-on funding depending on project scope and translational impact.
This highlighted topic is supported by numerous NIH Institutes and Offices including ODS, NCI, NEI, NHLBI, NIA, NIAMS, NIDCR, NIDDK, NINR, ODP, ONR, and OBSSR, all of which are seeking transformative innovations that improve metabolic health, nutrition science, chronic disease prevention, precision medicine, and evidence-based GLP-1 treatment strategies.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of metabolic health technologies, nutrition science platforms, AI analytics systems, digital therapeutics, biomarker tools, and dietary supplement evaluation technologies related to GLP-1 therapies and metabolic outcomes.
Eligible activities may include:
AI and machine learning platforms for GLP-1 treatment optimization and metabolic monitoring
Precision nutrition and personalized dietary intervention technologies
Biomarker discovery and metabolic risk prediction systems
Wearable devices and remote monitoring technologies for nutrition and body composition
Digital therapeutics supporting GLP-1 adherence and lifestyle interventions
Microbiome, metabolomics, and multi-omics analytics platforms
Dietary supplement testing, formulation, and bioavailability evaluation technologies
Real-world evidence and longitudinal outcomes research platforms
Cardiovascular, sleep, and metabolic disease prevention technologies
Cancer prevention and survivorship intervention systems related to GLP-1 use
Aging, cognitive health, and neurodegenerative disease research platforms
Musculoskeletal, bone density, sarcopenia, and fracture risk monitoring technologies
Oral health, ocular health, and inflammatory response assessment systems
Behavioral health, appetite regulation, and satiety analytics platforms
Drug interaction and safety assessment technologies for GLP-1 mimetics
Clinical decision support systems integrating nutrition and metabolic biomarkers
Prototype development, translational studies, and clinical validation research
Commercialization planning, regulatory preparation, and manufacturing scale-up activities
Funding may also support personnel, software engineering, cloud infrastructure, AI model development, laboratory testing, nutritional analysis, wearable integration, clinical research, bioinformatics analysis, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable healthcare, nutrition, or biotechnology solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
